SCHEMBL11945360

SCHEMBL11945360

O=c1c(OC2CCC2)c(N2CCN(S(=O)(=O)Cc3cccnc3)CC2)cnn1-c1cc(F)cc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ MMP13 P45452 2/20 0.38
▸ MMP14 P50281 2/20 0.38
▸ POLB P06746 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ NCOA2 Q15596 1/20 0.37
▸ NCOA1 Q15788 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ NCOA3 Q9Y6Q9 1/20 0.37
▸ GRM2 Q14416 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ DCTPP1 Q9H773 1/20 0.34
▸ HSD11B1 P28845 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ FKBP1A P62942 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944040 0.90 MAPT (0.40) MAPTMMP13MMP14POLBCYP2C19
SCHEMBL11945166 0.90 MAPT (0.45) MAPTPOLBCYP2C19CYP3A4PPARG
SCHEMBL11945144 0.89 MAPT (0.39) MAPTMMP13MMP14POLBCYP2C19
SCHEMBL11944776 0.89 MAPT (0.40) MAPTMMP13MMP14POLBCYP2C19
SCHEMBL11945123 0.89 MAPT (0.44) MAPTPOLBCYP2C19CYP3A4PPARG
SCHEMBL11945317 0.88 MAPT (0.49) MAPTMMP13MMP14POLBALDH1A1
SCHEMBL11945358 0.88 MAPT (0.38) MAPTMMP13MMP14POLBCYP2C19
SCHEMBL11945371 0.88 POLB (0.45) MAPTMMP13MMP14POLBCYP2C19
SCHEMBL11945356 0.88 MAPT (0.39) MAPTMMP13MMP14POLBCYP2C19
SCHEMBL14080992 0.86 MAPT (0.38) MAPTMMP13MMP14POLBCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885MMP13 3237/4885MMP14 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback